Literature DB >> 2203787

The activity of one soluble component of the cell-free NADPH:O2 oxidoreductase of human neutrophils depends on guanosine 5'-O-(3-thio)triphosphate.

B G Bolscher1, S W Denis, A J Verhoeven, D Roos.   

Abstract

Neutrophil NADPH:O2 oxidoreductase activity, essential in the killing of bacteria by neutrophils, can be elicited in a cell-free system that requires plasma membranes, cytosol and sodium dodecyl sulfate. In addition, GTP or its nonhydrolyzable analog guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) enhances NADPH oxidase activity. We investigated the mechanism of this effect of GTP gamma S in the cell-free system. Cytosol from human neutrophils was separated in three different soluble oxidase components (SOC I, SOC II, and SOC III). Previously we (Bolscher, B. G. J. M., Van Zwieten, R., Kramer, I. J. M., Weening, R. S., Verhoeven, A. J., and Roos, D. (1989) J. Clin. Invest. 83, 757-763) reported that the cytosol contains two components which act synergistically. We now report that one component (previously labeled SOC II) contains two different components that can be separated by ion exchange chromatography. Immunoblotting with antiserum B-1 (Volpp, B. D., Nauseef, W. M., and Clark, R. A. (1988) Science 242, 1295-1297), directed against a cytosolic complex capable of activating latent membranes in the cell-free system, showed a 47-kDa protein in SOC II and a 67-kDa protein in SOC III. SOC II also contains the 47-kDa phosphoprotein, which indicates that this phosphoprotein and the protein recognized by the antiserum are identical. Low rates of NADPH-dependent O2 consumption can be elicited by SOC II and SOC III in the absence of SOC I. This activity is independent of GTP gamma S. Addition of SOC I increases this activity 3-4-fold, only when GTP gamma S is present. Plasma membranes, incubated with SOC I plus GTP gamma S and re-isolated, showed a similar 3-4-fold enhanced O2 consumption with SOC II and SOC III. The GTP gamma S effect is exerted primarily at the level of the plasma membrane. The concentration of GTP gamma S that causes a half-maximal stimulation was 0.4 mu M. It is concluded that SOC I is a functional component of the NADPH oxidase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2203787

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Absolute requirement for GTP in activation of human neutrophil NADPH oxidase in a cell-free system: role of ATP in regenerating GTP.

Authors:  P Peveri; P G Heyworth; J T Curnutte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Involvement of GTP in cell-free activation of neutrophil NADPH oxidase. Studies with GTP analogues.

Authors:  E Klinger; I Aviram
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

3.  A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox.

Authors:  J H Leusen; M de Boer; B G Bolscher; P M Hilarius; R S Weening; H D Ochs; D Roos; A J Verhoeven
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 4.  The involvement of oxygen radicals in microbicidal mechanisms of leukocytes and macrophages.

Authors:  D Roos
Journal:  Klin Wochenschr       Date:  1991-12-15

Review 5.  Role of the Rho GTPase Rac in the activation of the phagocyte NADPH oxidase: outsourcing a key task.

Authors:  Edgar Pick
Journal:  Small GTPases       Date:  2014-03-05

6.  Resonance Raman microspectroscopy of myeloperoxidase and cytochrome b558 in human neutrophilic granulocytes.

Authors:  N M Sijtsema; C Otto; G M Segers-Nolten; A J Verhoeven; J Greve
Journal:  Biophys J       Date:  1998-06       Impact factor: 4.033

7.  156Pro-->Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox.

Authors:  J H Leusen; B G Bolscher; P M Hilarius; R S Weening; W Kaulfersch; R A Seger; D Roos; A J Verhoeven
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.